Get started
Author

María Presa

Observed names: M Presa, M. Presa, Maria Presa, María Presa González
ORCID: 0000-0001-5925-0619
Observed ORCID: 0000-0001-5925-0619
OpenAlex ID: A5039347595
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
2021 · Laia Alsina, J. Bruno Montoro, et al. · The European Journal of Health Economics · 27
Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
2022 · Vicente Estrada, Miguel Górgolas, et al. · PharmacoEconomics - Open · 15
PDF
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
2022 · Mariana Bastos-Oreiro, Ana de las Heras, et al. · Cancers · 14
PDF
Targeted screening for human immunodeficiency virus infection in Spanish emergency departments: an analysis of epidemiologic and economic impact.
2022 · José Moltó, Juan González Del Castillo, et al. · PubMed · 12
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients
2019 · María Presa, Fernando Pérez-Ruiz, et al. · Clinical Rheumatology · 10
PDF
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
2023 · María Presa, David Vicente, et al. · ClinicoEconomics and Outcomes Research · 9
PDF
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
2024 · Alejandro Martín García-Sancho, María Presa, et al. · Cancers · 7
Systematic review of the implantation of penile prosthesis in major ambulatory surgery
2022 · J. Torremadé, M. Presa, et al. · Actas Urológicas Españolas (English Edition) · 5
Toward Semantic Search for the Biogeochemical Literature
2017 · Joshua D. Eisenberg, Deya Banisakher, et al. · IEEE International Conference on Information Reuse and Integration (IRI) · 3
Análisis de los costes asociados a la administración intramuscular versus oral de la terapia antirretroviral en el manejo de la infección por el virus de la inmunodeficiencia humana
2024 · Vicente Estrada, Juan Emilio Losa, et al. · Enfermedades Infecciosas y Microbiología Clínica · 2
Cost-consequence analysis of penile prosthesis implantation in outpatient setting in Spain
2023 · Josep Torremadé, María Presa, et al. · International Journal of Healthcare Management · 2
PDF
Pcn108 Nivolumab-adjuvant Therapy for Resected Stage Iii-iv Melanoma: a Cost-effectiveness Analysis for Spain
2019 · M. Presa, A. Soria, et al. · Value in Health · 2
PDF
Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection
2024 · Vicente Estrada, Juan Emilio Losa, et al. · Enfermedades infecciosas y microbiologia clinica (English ed ) · 1
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
2024 · Raúl Córdoba, Lucía López-Corral, et al. · Cancers · 1
The process map of penile prosthesis implantation in outpatient surgery in Spain: a consensus documentMapa del proceso de implantación de prótesis de pene en cirugía mayor ambulatoria en España: documento de consenso
2024 · Óscar Gorría, Matilde Zaballos, et al. · Revista Internacional de Andrología · 1
PDF
Cost-effectiveness of microaxial flow pump versus standard of care in the management of Cardiogenic shock in Spain
2026 · Rut Andrea, Alfonso Jurado-Román, et al. · Expert Review of Pharmacoeconomics & Outcomes Research
Cost-effectiveness of microaxial flow pump versus standard of Care in the management of Cardiogenic shock in Spain
2026 · Rut Andrea, Alfonso Jurado-Román, et al. · Figshare
Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain
2026 · Sofía de Pedro, María Presa, et al. · PharmacoEconomics - Open
PDF
EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
2023 · V. Ortiz-Maldonado, M. Presa, et al. · Value in Health
PDF
EE193 Lorlatinib as a First-Line Treatment for ALK+ Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Spain
2022 · M Presa, D Vicente, et al. · Value in Health
PDF
CO76 Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
2022 · R Córdoba, L López-Corral, et al. · Value in Health
Revisión sistemática de la implantación de prótesis de pene en cirugía mayor ambulatoria
2022 · J. Torremadé, M. Presa, et al. · Actas Urológicas Españolas
POSA57 Axicabtagene Ciloleucel and Tisagenlecleucel for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
2022 · M Bastos-Oreiro, A de las Heras, et al. · Value in Health
Pcn241 Costs of Cytokine Release Syndrome (crs) and Neurological Events (ne) in Patients With Relapsed/refractory Non-hodgkin Lymphoma Receiving Lisocabtagene Maraleucel (liso-cel) in the Transcend Nhl 001 Clinical Trial: a Micro-costing Study From the Spanish National Health System (nhs) Perspective
2019 · M. Presa, C. Varela, et al. · Value in Health
PDF
Thu0048 2nd Line Treatment With Lesinurad and Allopurinol Versus Febuxostat for Management of Hyperuricemia: a Cost-effectiveness Analysis for Spanish Patients
2019 · María Presa, Fernando Perez-Ruiz, et al. · Annals of the Rheumatic Diseases
Works count: 25
Citation count: 111
H-index: 7
I10-index: 5
Year
Topic
Type